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Abstract 
Among the novel biologic therapeutics that will increase our ability to cure human cancer 
in the years to come, T cell therapy is one of the most promising approaches. However, 
with the possible exception of tumor-infiltrating lymphocytes therapy for melanoma, 
clinical trials of adoptive T-cell therapy for solid tumors have so far provided only clear 
proofs-of-principle  to  build  on  with  further  development.  Epstein-Barr  virus 
(EBV)-associated malignancies offer a unique model to develop T cell-based immune 
therapies, targeting viral antigens expressed  on tumor cells. In the last two decades, 
EBV-specific cytotoxic T-lymphocytes (CTL) have been successfully employed for the 
prophylaxis and  treatment  of  EBV-related  lymphoproliferative  disorders  in immuno-
compromised hosts. More recently, this therapeutic approach has been applied to the 
setting of EBV-related solid tumors, such as nasopharyngeal carcinoma. The results are 
encouraging, although further improvements to the clinical protocols are clearly neces-
sary to increase anti-tumor activity. Promising implementations are underway, including 
harnessing the therapeutic potential of CTLs specific for subdominant EBV latent cycle 
epitopes, and delineating strategies aimed at targeting immune evasion mechanisms ex-
erted by tumor cells. 
Key words: nasopharyngeal carcinoma, T-cell therapy, cytotoxic T lymphocytes, Epstein-Barr vi-
rus. 
Introduction 
The  development  of  new  agents  targeting  im-
portant  cellular  pathways  involved  in  cancer  pro-
gression, although promising, has so far resulted in 
relatively short-term benefits for the majority of pa-
tients with advanced malignancy. Cell therapy can be 
numbered among the novel biologic therapeutics that 
will increase our ability to cure human disease in the 
years  to  come.  Despite  the  great  potential,  T  cell 
therapy  for  cancer  still  has  a  marginal  role  in  the 
management of patients with neoplasia. This is due to 
limitations inherent to the technologies and products 
employed, and, more importantly, to the financial and 
structural requirements that are associated with cell 
therapy [1-3]. 
Clinical application was first attempted by Ros-
enberg  and  colleagues  in  1985  by  using  LAK  cells, 
infused  with  IL-2  into  patients  with  different  ad-
vanced  malignancies  [4]:  response  was  observed  in 
four kinds of solid tumors, thus paving the way to 
further  investigations.  Afterwards,  several  experi-
mental and clinical studies were conducted: cell types 
tested included CIK cells [5], tumor infiltrating lym-
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phocytes  (TILs)  [6,7,8]  and  other  T-cells  variously 
manipulated [1,3,9-11], which were used in different 
settings,  from  solid  cancers  to  the  transplantation 
field. 
Among the factors that so far limited a wider use 
of T cell therapy for human tumors may be the very 
low  frequency  of  tumor-specific  lymphocytes  circu-
lating in patients with cancer, or the limited ability to 
induce T cell lines with protective antitumor activity 
with  current  knowledge  and  available  technology. 
With the exception of TIL therapy in melanoma, the 
only other human solid cancer setting in which tu-
mor-specific T cells have been employed with success 
is virus-related tumors. Indeed, when the frequency 
of circulating T cells against the target antigen on a 
tumour is high, as is the case for viral antigens, T cell 
therapy can be very effective in destroying large tu-
mours in humans. In this context, EBV-positive ma-
lignancies provide an optimal model system to test 
and  ameliorate  cellular  therapies:  the  first  very  en-
couraging results were reached with prophylaxis and 
treatment of posttransplant lymphoproliferative dis-
ease [9-11]; the success of this approach has fostered 
research  in  other,  more  complex  areas,  such  as 
EBV-related solid tumors. 
Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is a rare can-
cer in the Western hemisphere where its incidence is 
approximately  1  case  per  100,000  individuals;  con-
versely there are some areas, such as Southern China, 
Southeast Asia, the Mediterranean basin and Alaska, 
where it reaches 80 per 100,000 individuals: moreover 
in the western hemisphere the tumor histology differs 
from  the  endemic  form  [12].  All  these  differences 
suggest that an important role in the pathogenesis is 
played by genetic and environmental factors. 
The  current  WHO  classification  defines  naso-
pharyngeal cancer a carcinoma that shows light mi-
croscopic  or  ultrastructural  evidence  of  squamous 
differentiation.  It  encompasses  squamous  cell  carci-
noma, associated with behavioural risk factors such as 
alcohol and tobacco use, non keratinizing carcinoma 
(differentiated  and  undifferentiated)  and  basaloid 
squamous cell carcinoma [13]. The most common pe-
diatric  nasopharyngeal  carcinoma  is  the 
non-keratinizing undifferentiated carcinoma [14] and 
is associated  with  EBV  in  practically  100%  of  cases 
[13]. 
Although NPC is serologically and biologically 
associated with Epstein-Barr Virus, NPC cells express 
only a limited pattern of EBV genes (the so-called la-
tency II pattern) which comprises non-coding RNAs 
(EBERs,  BARTs),  the  nuclear  antigen  EBNA1  and 
surface antigens LMP1 and LMP2 [15], immunogens 
that  are  weak,  albeit  capable  of  inducing  a 
T-lymphocyte response . 
In most cases the tumor presents as a painless 
mass in the upper neck, with possible cervical lym-
phadenopathy. The most common pattern of tumor 
diffusion  is  local  infiltration  which,  given  the  limi-
trophe  structures,  may  cause  serous  otitis,  hearing 
difficulties,  nasal  obstruction,  epistaxis,  dysphasia, 
dysphonia  and  dysphagia.  NPC  can  metastatize  to 
lung, bone, mediastinum, bone marrow and visceral 
organs [13,16,17]. Paraneoplastic syndromes may also 
be present, in most cases related to tumor dissemina-
tion or relapse, such as hypertrophic osteoarthropa-
thy, leukemoid reaction, FUO, dermatomyositis, and 
inappropriate ADH secretion syndrome [18].  
The extent of the tumor at diagnosis is described 
by  the  TNM  classification  of  the  American  Joint 
Committee on Cancer; in children, as in adults, the 
TNM stage at the time of diagnosis correlates  with 
outcome  [19].  However,  with  more  advanced  and 
improved treatments, while the presence of metasta-
ses continues to be associated with poor outcome, T 
and N staging are losing prognostic significance [20, 
21].  
NPC  is  highly  sensitive  to  both  radio-  and 
chemotherapy. Radiotherapy is a cornerstone of first 
line therapy and it is the standard treatment for ear-
ly-stage  NPC  (T1-2a;  N0;  M0):  patients  with  local 
disease  can  be  adequately  treated  with  radiation 
alone, with a 5-years control ranging from 80 to 95% 
of cases [22-25] .  
Treatment strategies for locally advanced NPC 
consists mainly of platinum based chemotherapy in 
conjunction with radiotherapy, and yields an overall 
response rate of about 90%, with complete response 
ranging from 20 to 50% [26-28]. Induction treatment is 
able to improve local regional control, which trans-
lates into long-term specific survival benefits. In lo-
cal-regional  recurrent  nasopharyngeal  cancer  not 
amenable  for  reirradiation,  combination  cispla-
tin-based chemotherapy is a standard first line treat-
ment, with response rates of 40-80%, mainly depend-
ing on the site of lesions, previous treatment, disease 
free interval [28,29]. No standard second-line chemo-
therapy has been defined, but a recent study reported 
an 11% response rate in recurrent and metastatic dis-
ease by combining target therapy (cetuximab) to car-
boplatin [30]. However, the benefits of this treatment 
are  generally  short-lived.  Second  line  therapies  in 
refractory/relapsing patients usually have little effect 
on  the  natural  history  of  the  disease,  and  there  is 
therefore  a  need  to  develop  additional  forms  of Journal of Cancer 2011, 2 
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treatment,  particularly  ones  that  lack  overlapping 
toxicities with radiochemotherapy [31,32].  
Cell therapy for NPC 
Clinical results 
In the last 15 years, a number of reports demon-
strated  the  effectiveness  of  ATCT  directed  against 
EBV antigens for the treatment of EBV-related hema-
tological  malignancies  in  the  immunocompromised 
host  [3,9-11,33].  EBV-related  posttransplant  lym-
phoproliferative disease (PTLD) constitutes a highly 
immunogenic  lymphoproliferation  whose  onset  is 
greatly favoured by the host immunodeficiency sta-
tus. Thus, T cell therapy in this setting is expected to 
have a great chance of success. Adoptive transfer of 
polyclonal CTLs specific for viral latency antigens in 
the context of EBV-associated malignancies arising in 
the immunocompetent host, such as nasopharyngeal 
carcinoma (NPC), is hampered by a number of factors 
[34]. EBV-specific CTLs are dominated by reactivity 
against viral proteins not expressed by these tumors. 
Moreover, the transferred CTLs have to compete with 
endogenous lymphocytes for cytokines and biological 
niches, and, once CTLs reach the tumor site, they have 
to  overcome  the  inhibitory  barriers  exerted  by  the 
tumor  environment.  Notwithstanding  these  limita-
tions,  the  results  of  the  clinical  cell  therapy  trials 
conducted  so  far  in  NPC  patients  demonstrate  that 
administration of an avid anti-tumour T cell targeting 
a  highly  expressed  antigen  can  result  in  cancer  re-
gression [35,36]. 
To date, a total  of 57 patients with NPC were 
treated  within  phase  I-II  clinical  trials  [35-41].  In  a 
phase I study, Comoli et al. [35] enrolled 10 patients 
with stage IV NPC in progression after conventional 
radiotherapy and chemotherapy. Patients underwent 
multiple  (from  2  to  23)  infusions  of  autologous 
EBV-specific CTLs with a dose ranging from 2 to 8x107 
cells /m2, accompanied by administration of low-dose 
(1x106U) recombinant IL-2 with the purpose of pro-
longing T-lymphocyte life-span. There were no major 
adverse events, although two patients suffered from 
moderate  inflammatory  reactions  at  the  tumor  site. 
Control of disease progression was obtained in six of 
ten patients (two with partial response and four with 
stable  disease).  More  importantly,  it  was  demon-
strated that tumor control related to cell therapy did 
occur,  and  was  associated  to  the  emergence  or  in-
crease  in  LMP2-specific  responses  in  the  peripheral 
blood. In the same year, Straathof and colleagues [36] 
published data from 10 patients with advanced NPC. 
In a recent update [37] Louis added 13 new patients to 
the previous 10 (whose follow-up was extended), for a 
total of 23 patients treated. Of these patients (all but 
one with stage III-IV NPC) eight were in disease re-
mission at the time of the first infusion and 15 had 
active disease. They were treated with a mean of 2 
infusions with a dose ranging from 2x107 cells/m2 to 
2x108 cells /m2, in the absence of IL-2 use. The therapy 
was  well  tolerated:  only  one  patient  experienced 
marked swelling at the tumor site requiring a trache-
ostomy. Of the eight patients treated in remission five 
remained disease-free for 25 to 82 months and three 
suffered from disease relapse. Of the other 15 patients 
treated with active disease ten showed control of the 
disease  (5  with  Complete  Response,  2  with  Partial 
Response, 3 with Stable Disease), while the other five 
progressed. Prior to these two studies, one pilot study 
in China showed that the adoptive transfer of autol-
ogous EBV-targeted CTLs induced antiviral responses 
but no clinical responses in 4 NPC patients [40], while 
adoptive transfer of allogeneic EBV-specific CTL in-
duced  a  clinical  response  in  a  patient  with  ad-
vanced-stage NPC, likely associated to a boost in en-
dogenous LMP2-specific response [41]. 
The  data  obtained  with  these  early  studies 
prompted further efforts aimed at enhancing the ex-
pansion  potential  of  infused  T-cells,  by  means  of  a 
lymphodepleting treatment prior to CTL infusion, as 
demonstrated  in  the  context  of  T-cell  therapy  for 
melanoma [42,43].  
In a pilot study, 8 patients with loco-regional or 
metastatic refractory/recurrent NPC were given an-
ti-CD45 monoclonal antibody treatment, followed by 
escalating doses of polyclonal EBV-specific CTL. After 
transitory lymphodepletion, and increase in the cir-
culating  levels  of  IL-15,  3  objective  responses  were 
seen, in the patients who showed higher increase in 
their  peripheral  blood  frequency  of  EBV-specific  T 
cells  after  CTL  infusion  [38].  Secondino  and  col-
leagues [39] enrolled 11 heavily pre-treated patients 
with  active  stage  IV  NPC,  who  received 
non-myeloablative  lymphodepleting  chemotherapy 
consisting of cyclophosphamide and fludarabine: two 
doses of autologous EBV-specific CTLs (median dose 
of 3.7x108cells) were subsequently infused, two weeks 
apart, supported by low-dose IL-2. Control of disease 
was obtained in six of eleven patients (3 with stable 
disease, 2 with partial response and one with minor 
response). Two patients experienced mild to moder-
ate swelling at the disease site. Notwithstanding the 
encouraging  preliminary  results,  the  use  of  lym-
phodepleting  preparative  regimens  as  a  mean  to 
overcome the inhibitory checkpoints devised by the 
tumor cells is a strategy that needs further optimiza-
tion.  Journal of Cancer 2011, 2 
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To summarize, data collected from a total of 57 
patients  receiving  polyclonal,  EBV-polyspecific  CTL 
were as follows: 
1)  of  30  patients  with  advanced,  active  NPC, 
treated  with  autologous  or  allogeneic,  polyclonal 
EBV-specific CTL infusions, 17 (56%) achieved control 
of the disease (defined as either tumor regression or 
disease stabilization) 
2)  of  19  patients  with  advanced,  active  NPC, 
treated with autologous, polyclonal EBV-specific CTL 
infusions preceded by a lymphodepleting regimen 9 
(47%) achieved control of the disease 
3) of 8 patients treated in disease remission, alt-
hough at great risk of relapse, at the time of the first 
infusion, 5 (62%) remained disease-free for 25 to 82 
months and 3 suffered from relapsing disease 
Considerations on clinical data and on future 
strategies to ameliorate outcome 
T cell therapy, although now frequently used in 
the hematopoietic transplantation setting, has not yet 
been widely introduced in the clinical oncologic field 
and  is  currently  limited  to  research  protocols  in 
highly-specialized centres. For solid tumors, the ma-
jority  of  the  literature  available  nowadays  refers  to 
treatment of melanoma [42]. The phase I-II studies of 
EBV-targeted T cell therapy for NPC, taken together, 
provide  one  of  the  larger  series  for  non-melanoma 
solid  malignancies.  These  studies  provide  new  per-
spectives on the optimal treatment for metastatic or 
recurrent  disease;  indeed,  to  date,  cisplatin-based 
chemotherapy is considered the preferred regimen for 
such patients: response rates are above 50% and me-
dian survival is approximately 12 months [26]. How-
ever, the choice for second-line regimens in patients 
with  unsatisfactory  responses  to  a  platinum-based 
treatment remains unclear [32]. 
In the cell therapy trials described, the patients 
enrolled were a heavily pre-treated cohort with a very 
poor prognosis. In these patients, further conventional 
treatment  would  likely  lead  to  a  very  high  risk  of 
toxicity,  ranging  from  26%  after  re-irradiation  with 
high dose radiotherapy [44] to 89% after conventional 
cytotoxic  protocols  [45].  In  the  cohort  treated  with 
CTLs, there were only five out of 52 patients (less than 
10%) who suffered from swelling at the tumor site; of 
these, four had mild to moderate inflammatory reac-
tions [35, 39] and only one had a major complication 
[36]. In particular this patient, who presented bulky 
disease and pre-existing facial swelling, two days af-
ter the first infusion, developed marked worsening of 
the tumefaction requiring a tracheostomy: the authors 
performed a needle biopsy which showed tumor cells, 
but  not  inflammatory  cells,  suggesting  tumor  pro-
gression rather than an inflammatory reaction. Thus 
the safety and the feasibility of this approach, even at 
the highest doses reached, is more than a supposition. 
The second point to take into consideration is the 
efficacy  of  this  therapy:  taken  grossly  together  all 
these data show a response rate ranging from 47 to 
64%, thus perfectly in line with other types of second-, 
third- or more advanced therapy [32]. For the patients 
treated in remission, given the small size of the cohort, 
the role of infused CTLs remains unclear.  
But, more importantly, these data raise a number 
of questions, which remains, to date, unresolved. First 
of all, what is the role and the best timing of adoptive 
T-cell therapy in NPC? The studies published to date 
indicate  that  CTLs  could  possibly  be  administered 
earlier  the  course  of  treatment  and  in  combination 
with conventional therapies (for example as consoli-
dation treatment after achieving response to second 
line therapy) [39].  
Furthermore, immune escape can occur even in 
instances when polyclonal antigen-specific T cells are 
infused [46]: Gottschalk et al reported a patient with 
EBV-positive lymphoproliferative disease, who failed 
EBV-specific T-cell therapy, in which the tumor virus 
had deleted immunodominant EBV epitopes [47]. In 
the setting of NPC immune escape could represent an 
even more relevant problem. A strategy to overcome 
this  phenomenon,  and  to  increase  clinical  efficacy 
through better targeting, could be to ameliorate the 
quality of the cell product. In this perspective, efforts 
are  being  made  towards  augmenting  the  pool  of 
T-cells  specific  for  the  subdominant  antigens  ex-
pressed on EBV latency II tumor cells within the in-
fused product, with the aim of increasing T cell ther-
apy efficacy. In detail, the subdominant component of 
the EBV-specific immune response directed towards 
latent membrane proteins LMP1 and LMP2 has been 
shown to expand, by stimulation with dendritic cells 
or EBV-LCL genetically modified to express the anti-
gens [48-50]. In a pilot study enrolling EBV-positive 
Hodgkin or non-Hodgkin lymphoma, 5 of 6 patients 
with active relapsed disease showed a tumor response 
after infusion of autologous LMP2-specific CTL [51]. 
Similar studies in NPC cohorts are warranted. 
A barrier to the function of infused EBV-specific 
CTLs  in  immunocompetent  hosts  is  the  display  of 
tumor-mediated immune evasion strategies  [52].  To 
improve the resistance of CTLs to tumor-derived in-
hibitory  cytokines,  Bollard  et  al.  have  shown  that 
EBV-specific  CTL  made  transgenic  for  a  domi-
nant-negative TGF-receptor, in which the intracel-
lular signaling domain is truncated, are rendered re-
sistant to the devastating effects of TGF-, secreted by 
Hodgkin tumor cells [53]. Likewise, treatment failure Journal of Cancer 2011, 2 
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due to lack or loss of EBV antigen expression by neo-
plastic cell subpopulations may be avoided through 
redirecting EBV-specific CTLs to target other tumor 
antigens. It has been shown that EBV-specific CTLs 
expressing a chimeric antigen receptor (CAR) specific 
for  CD30,  a  molecule  highly  and  consistently  ex-
pressed on malignant Hodgkin Reed-Sternberg cells, 
while retaining their original specificity, are also able 
to target CD30+ neoplastic cells, and mediate activity 
against  EBV-/CD30+  tumors  in  a  xenograft  model 
[54]. 
Conclusions 
The  management  of  human  cancer  with  ra-
dio-chemotherapy is still suboptimal, due to persis-
tence  of  refractory/relapsing  disease,  and  the  in-
creased  toxicity  observed with  increased  efficacy  of 
therapeutic  regimens.  Targeted  therapies  may  offer 
equal or increased efficacy, coupled with a consider-
able decrease in overall toxicity. Among these novel 
approaches, cell therapy offers a unique opportunity 
to  restore antitumor  immune  surveillance,  and  it  is 
therefore conceivable that application of this strategy 
will increase in the next few years [55]. In particular, 
for patients with relapsed or refractory NPC which 
express  EBV  antigens,  autologous,  polyclonal, 
EBV-specific CTL therapy is safe, feasible, with low 
complication rates and a significant clinical response. 
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